J Heart Lung Transplant

• 

  Publication Venue For

  • Early posttransplant reductions in club cell secretory protein associate with future risk for chronic allograft dysfunction in lung recipients: results from a multicenter study..  42:741-749. 2023
  • The 2023 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: A 10- Year Update. 2023
  • Erratum to Survival difference between high-risk and low-risk CFTR genotypes after lung transplant. J Heart Lung Transpl 2022;41(10):1511-19. https://doi.org/10.1016/j.healun.2022.04.009..  42:688. 2023
  • Imaging the right atrium in pulmonary hypertension: A systematic review and meta-analysis..  42:433-446. 2023
  • Real-time transcription polymerase chain reaction cycle threshold values as criteria for utilization of incidental COVID-19 positive lung donors..  42:301-304. 2023
  • A report of the first pediatric heart transplant following donation after circulatory death in the United States using ex-vivo perfusion..  42:287-288. 2023
  • Bloodless HeartMate 3 explantation and orthotopic heart transplant in a heart failure patient refusing blood products..  41:1859-1860. 2022
  • Contemporary trends in PGD incidence, outcomes, and therapies..  41:1839-1849. 2022
  • Remote ex vivo lung perfusion at a centralized evaluation facility..  41:1700-1711. 2022
  • Textbook outcome in lung transplantation: Planned venoarterial extracorporeal membrane oxygenation versus off-pump support for patients without pulmonary hypertension..  41:1628-1637. 2022
  • Lung allograft standardized histological analysis (LASHA) template: A research consensus proposal..  41:1487-1500. 2022
  • The Future of heart procurement with donation after circulatory death: Current practice and opportunities for advancement..  41:1385-1390. 2022
  • Transplanting thoracic COVID-19 positive donors: An institutional protocol and report of the first 14 cases..  41:1376-1381. 2022
  • Genetic cardiomyopathies and clinical implications in heart transplant recipients: An opportunity for missed diagnoses..  41:1195-1197. 2022
  • Pulmonary artery pulsatility index as a predictor of right ventricular failure in left ventricular assist device recipients: A systematic review..  41:1114-1123. 2022
  • Recovery of left ventricular function is associated with improved outcomes in LVAD recipients..  41:1055-1062. 2022
  • Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis..  41:508-515. 2022
  • Relationship of ventricular assist device support duration with pediatric heart transplant outcomes..  41:61-69. 2022
  • Practice variation in the diagnosis of acute rejection among pediatric heart transplant centers: An analysis of the pediatric heart transplant society (PHTS) registry..  40:1550-1559. 2021
  • Proteomic profiling identifies CLEC4C expression as a novel biomarker of primary graft dysfunction after heart transplantation..  40:1589-1598. 2021
  • Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation..  40:1349-1379. 2021
  • Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT..  40:1301-1326. 2021
  • ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part I: Epidemiology, assessment of extrapulmonary conditions, candidate evaluation, selection criteria, and pathology statements..  40:1251-1266. 2021
  • ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part II: Cardiac, surgical, perioperative, operative, and post-operative challenges and management statements..  40:1267-1278. 2021
  • ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements..  40:1279-1300. 2021
  • Bone marrow-derived AXL tyrosine kinase promotes mitogenic crosstalk and cardiac allograft vasculopathy..  40:435-446. 2021
  • Clinical outcomes and healthcare expenditures in the real world with left ventricular assist devices - The CLEAR-LVAD study..  40:323-333. 2021
  • Risk of primary graft dysfunction following lung transplantation in selected adults with connective tissue disease-associated interstitial lung disease..  40:351-358. 2021
  • Hyperbaric oxygen therapy to prevent central airway stenosis after lung transplantation..  40:269-278. 2021
  • COVID-19 vaccination in our transplant recipients: The time is now..  40:169-171. 2021
  • Risk factors for mortality in lung transplant recipients aged ≥65 years: A retrospective cohort study of 5,815 patients in the scientific registry of transplant recipients..  40:42-55. 2021
  • The Journal of Heart and Lung Transplantation: A golden age draws to a close and a new dawn begins..  40:3. 2021
  • Identifying host microRNAs in bronchoalveolar lavage samples from lung transplant recipients infected with Aspergillus..  39:1228-1237. 2020
  • International Society for Heart and Lung Transplantation consensus statement for the standardization of bronchoalveolar lavage in lung transplantation..  39:1171-1190. 2020
  • Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations..  39:1050-1069. 2020
  • Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: Baseline results from the Pulmonary Hypertension Association Registry..  39:945-953. 2020
  • Bronchoalveolar bile acid and inflammatory markers to identify high-risk lung transplant recipients with reflux and microaspiration..  39:934-944. 2020
  • Extended post-ex vivo lung perfusion cold preservation predicts primary graft dysfunction and mortality: Results from a multicentric study..  39:954-961. 2020
  • Multimodal analgesia using opioid-sparing regimen in patients undergoing left ventricular assist device implantation..  39:977-979. 2020
  • Left ventricular assist systems and infection-related outcomes: A comprehensive analysis of the MOMENTUM 3 trial..  39:774-781. 2020
  • PREVENTion of non-surgical bleeding by management of HeartMate II patients without anti-platelet therapy (PREVENT II) trial..  39:838-840. 2020
  • Putting the 2019 CLAD consensus definitions to the test: Two steps forward, one step back?.  39:771-773. 2020
  • Secondary Pulmonary Hypertension; getting down to the nuts and BOLT. Author's reply to Ranganath et al..  39:851. 2020
  • Exploring differences between patients who accept, decline, and are deemed ineligible for left ventricular assist device implantation as destination therapy..  39:721-724. 2020
  • Understanding risk factors and predictors for stroke subtypes in the ENDURANCE trials..  39:639-647. 2020
  • Donor fraction cell-free DNA and rejection in adult and pediatric heart transplantation..  39:454-463. 2020
  • Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement..  39:418-432. 2020
  • A Clinical Study to Evaluate Ambulatory Counterpulsation for the Treatment of Advanced Heart Failure: A Feasibility Study.  39:S52-S53. 2020
  • Association of Discharge Immunosuppression Regimen and Post-Transplant Outcomes in Lung Transplantation: An Analysis of OPTN Data.  39:S126. 2020
  • Early Bleeding is Associated with Increased Length of Stay and Early Death in LVAD Recipients.  39:S49. 2020
  • Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients without Antiplatelet Therapy.  39:S48-S49. 2020
  • The Impact of HeartMate 3 Speed on Outcomes in the Momentum 3 Clinical Trial.  39:S184-S185. 2020
  • Variability in donor organ offer acceptance and lung transplantation survival..  39:353-362. 2020
  • American Association for Thoracic Surgery/International Society for Heart and Lung Transplantation guidelines on selected topics in mechanical circulatory support..  39:187-219. 2020
  • Quality of life and treatment preference for ventricular assist device therapy in ambulatory advanced heart failure: A report from the REVIVAL study..  39:27-36. 2020
  • Adipose tissue quantification and primary graft dysfunction after lung transplantation: The Lung Transplant Body Composition study..  38:1246-1256. 2019
  • Bilateral pneumonectomy with veno-arterial extracorporeal membrane oxygenation as a bridge to lung transplant..  38:1231-1232. 2019
  • Single lung transplantation in patients with severe secondary pulmonary hypertension..  38:939-948. 2019
  • Usefulness of gene expression profiling of bronchoalveolar lavage cells in acute lung allograft rejection..  38:845-855. 2019
  • Beyond the eyeball test: Measures of frailty in lung transplantation..  38:708-709. 2019
  • Chronic lung allograft dysfunction: Definition and update of restrictive allograft syndrome-A consensus report from the Pulmonary Council of the ISHLT..  38:483-492. 2019
  • Epidemiology of infection in mechanical circulatory support: A global analysis from the ISHLT Mechanically Assisted Circulatory Support Registry..  38:364-373. 2019
  • Outcomes with ambulatory advanced heart failure from the Medical Arm of Mechanically Assisted Circulatory Support (MedaMACS) Registry..  38:408-417. 2019
  • Implications of declining donor offers with increased risk of disease transmission on waiting list survival in lung transplantation..  38:295-305. 2019
  • Prognostic significance of early pulmonary function changes after onset of chronic lung allograft dysfunction..  38:184-193. 2019
  • Implications of blood group on lung transplantation rates: A propensity-matched registry analysis..  38:73-82. 2019
  • Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study..  38:43-50. 2019
  • Pre-transplant weight loss and clinical outcomes after lung transplantation..  37:1443-1447. 2018
  • Bloodstream infections in mechanical circulatory support device recipients in the International Society of Heart and Lung Transplantation Mechanically Assisted Circulation Support Registry: Epidemiology, risk factors, and mortality..  37:1013-1020. 2018
  • Late manifestation of alloantibody-associated injury and clinical pulmonary antibody-mediated rejection: Evidence from cell-free DNA analysis..  37:925-932. 2018
  • Left ventricular assist devices versus medical management in ambulatory heart failure patients: An analysis of INTERMACS Profiles 4 and 5 to 7 from the ROADMAP study..  37:706-714. 2018
  • Acute kidney injury and 1-year mortality after left ventricular assist device implantation..  37:116-123. 2018
  • Early intervention for lactate dehydrogenase elevation improves clinical outcomes in patients with the HeartMate II left ventricular assist device: Insights from the PREVENT study..  37:25-32. 2018
  • Impact of age, sex, therapeutic intent, race and severity of advanced heart failure on short-term principal outcomes in the MOMENTUM 3 trial..  37:7-14. 2018
  • Pre-operative proteinuria in left ventricular assist devices and clinical outcome..  37:124-130. 2018
  • Bleeding and thrombosis associated with ventricular assist device therapy..  36:1164-1173. 2017
  • Usefulness of 2 centrifugal ventricular assist devices in a total artificial heart configuration: A preliminary report..  36:1266-1268. 2017
  • Report of the ISHLT Working Group on primary lung graft dysfunction Part IV: Prevention and treatment: A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation..  36:1121-1136. 2017
  • Applying rigor and reproducibility standards to assay donor-derived cell-free DNA as a non-invasive method for detection of acute rejection and graft injury after heart transplantation..  36:1004-1012. 2017
  • Extracorporeal membrane oxygenation following lung transplantation: indications and survival. 2017
  • The utility of 6-minute walk distance in predicting waitlist mortality for lung transplant candidates..  36:780-786. 2017
  • The new United States heart allocation policy: Progress through collaborative revision..  36:595-596. 2017
  • Clinical predictors and outcome implications of early readmission in lung transplant recipients..  36:546-553. 2017
  • Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices..  36:380-385. 2017
  • The wait for the waitlist: The next challenge in the lung allocation system..  36:250-252. 2017
  • Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality..  36:202-210. 2017
  • Extracorporeal membrane oxygenation support and post-heart transplant outcomes among United States adults..  36:77-81. 2017
  • PREVENtion of HeartMate II Pump Thrombosis Through Clinical Management: The PREVENT multi-center study..  36:1-12. 2017
  • Pump speed modulations and sub-maximal exercise tolerance in left ventricular assist device recipients: A double-blind, randomized trial..  36:36-41. 2017
  • The incidence, risk factors, and outcomes associated with late right-sided heart failure in patients supported with an axial-flow left ventricular assist device..  36:50-58. 2017
  • Right ventricular afterload sensitivity dramatically increases after left ventricular assist device implantation: A multi-center hemodynamic analysis..  35:868-876. 2016
  • Thrombus around the redesigned HeartWare HVAD inflow cannula: A pathologic case series..  35:926-930. 2016
  • High early event rates in patients with questionable eligibility for advanced heart failure therapies: Results from the Medical Arm of Mechanically Assisted Circulatory Support (Medamacs) Registry..  35:722-730. 2016
  • Trends and outcomes of patients with adult congenital heart disease and pulmonary hypertension listed for orthotopic heart transplantation in the United States..  35:619-624. 2016
  • Antibody-mediated rejection of the lung: A consensus report of the International Society for Heart and Lung Transplantation..  35:397-406. 2016
  • The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia..  35:500-507. 2016
  • Cardiac transplantation for older patients: Characteristics and outcomes in the septuagenarian population..  35:362-369. 2016
  • The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: Executive summary..  35:261-282. 2016
  • Impact of donor and recipient hepatitis C status in lung transplantation..  35:228-235. 2016
  • Banff study of pathologic changes in lung allograft biopsy specimens with donor-specific antibodies..  35:40-48. 2016
  • Benefits of a novel percutaneous ventricular assist device for right heart failure: The prospective RECOVER RIGHT study of the Impella RP device..  34:1549-1560. 2015
  • One-and-done: Do left ventricular assist device patients on the transplant list really need frequent right heart catheterization assessments for pulmonary hypertension?.  34:1637-1639. 2015
  • Pump thrombosis in the Thoratec HeartMate II device: An update analysis of the INTERMACS Registry..  34:1515-1526. 2015
  • Safety of reduced anti-thrombotic strategies in HeartMate II patients: A one-year analysis of the US-TRACE Study..  34:1542-1548. 2015
  • Who wants a left ventricular assist device for ambulatory heart failure? Early insights from the MEDAMACS screening pilot..  34:1630-1633. 2015
  • Fontan-associated protein-losing enteropathy and heart transplant: A Pediatric Heart Transplant Study analysis..  34:1169-1176. 2015
  • Development and psychometric properties of the Pulmonary-specific Quality-of-Life Scale in lung transplant patients..  34:1058-1065. 2015
  • Incremental and independent value of cardiopulmonary exercise test measures and the Seattle Heart Failure Model for prediction of risk in patients with heart failure..  34:1017-1023. 2015
  • A multicenter analysis of clinical hemolysis in patients supported with durable, long-term left ventricular assist device therapy..  34:701-709. 2015
  • Determining eligibility for lung transplantation: A nationwide assessment of the cutoff glomerular filtration rate..  34:571-579. 2015
  • Serial monitoring of exhaled nitric oxide in lung transplant recipients..  34:557-562. 2015
  • Reliability of transthoracic echocardiogram interpretation in potential adult heart transplant donors..  34:266-269. 2015
  • Reliability of echocardiographic measurements of left ventricular systolic function in potential pediatric heart transplant donors..  34:100-106. 2015
  • De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantation..  33:1288-1294. 2014
  • The Chronic Kidney Disease Epidemiology Collaboration (CKDEPI) equation best characterizes kidney function in patients being considered for lung transplantation..  33:1248-1254. 2014
  • Organ allocation around the world: insights from the ISHLT International Registry for Heart and Lung Transplantation..  33:975-984. 2014
  • A contemporary review of mechanical circulatory support..  33:667-674. 2014
  • Cromolyn ameliorates acute and chronic injury in a rat lung transplant model..  33:749-757. 2014
  • Concomitant tricuspid valve surgery during implantation of continuous-flow left ventricular assist devices: a Society of Thoracic Surgeons database analysis..  33:609-617. 2014
  • Report from a consensus conference on primary graft dysfunction after cardiac transplantation..  33:327-340. 2014
  • A novel link between G6PD deficiency and hemolysis in patients with continuous-flow left ventricular assist devices..  33:116-117. 2014
  • Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device..  33:12-22. 2014
  • After-hour ventricular assist device coverage: what level of expertise is required?.  32:1272-1274. 2013
  • Algorithm for the diagnosis and management of suspected pump thrombus..  32:667-670. 2013
  • Rituximab-associated progressive multifocal leukoencephalopathy after lung transplantation..  32:752-753. 2013
  • Rituximab-associated progressive multifocal leukoencephalopathy after lung transplantation..  32:752-753. 2013
  • The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary..  32:157-187. 2013
  • Statement regarding the pre and post market assessment of durable, implantable ventricular assist devices in the United States..  31:1241-1252. 2012
  • A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation..  31:942-949. 2012
  • Pilot investigation of a novel testing strategy for bleeding in ventricular assist device recipients..  31:750-756. 2012
  • Editorial Commentary: Determining the cost-effectiveness of mechanical circulatory support..  31:448-449. 2012
  • Development of a quantitative donor risk index to predict short-term mortality in orthotopic heart transplantation..  31:266-273. 2012
  • Editorial commentary: renal failure after cardiac transplantation: of bravery, wisdom and honesty..  31:231-232. 2012
  • Insurance and education predict long-term survival after orthotopic heart transplantation in the United States..  31:52-60. 2012
  • Neurocognitive function in destination therapy patients receiving continuous-flow vs pulsatile-flow left ventricular assist device support..  31:27-36. 2012
  • Recurrence of heart failure symptoms after LVAD placement due to bradycardia-induced inflow obstruction..  31:111-113. 2012
  • Marital status improves survival after orthotopic heart transplantation..  30:1389-1394. 2011
  • Exercise blood pressure response during assisted circulatory support: comparison of the total artificial [corrected] heart with a left ventricular assist device during rehabilitation..  30:1207-1213. 2011
  • Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial..  30:990-996. 2011
  • Inhaled nitric oxide after left ventricular assist device implantation: a prospective, randomized, double-blind, multicenter, placebo-controlled trial..  30:870-878. 2011
  • Presentation and management of left ventricular assist device inflow cannula malposition..  30:838-840. 2011
  • Innate immune activation potentiates alloimmune lung disease independent of chemokine (C-X-C motif) receptor 3..  30:717-725. 2011
  • Working formulation for the standardization of definitions of infections in patients using ventricular assist devices..  30:375-384. 2011
  • Report from a consensus conference on antibody-mediated rejection in heart transplantation..  30:252-269. 2011
  • Infectious complications after pulsatile-flow and continuous-flow left ventricular assist device implantation..  30:164-174. 2011
  • Construct validity of the definition of primary graft dysfunction after lung transplantation..  29:1231-1239. 2010
  • The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients..  29:914-956. 2010
  • Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy..  29:616-624. 2010
  • Ideal methodology to assess systemic blood pressure in patients with continuous-flow left ventricular assist devices..  29:593-594. 2010
  • Clinical management of continuous-flow left ventricular assist devices in advanced heart failure..  29:S1-39. 2010
  • Quality of life and functional status in patients surviving 12 months after left ventricular assist device implantation..  29:278-285. 2010
  • Routine performance of endomyocardial biopsy decreases the incidence of orthotopic heart transplant for myocarditis..  28:1261-1266. 2009
  • Impact of recipient body mass index on organ allocation and mortality in orthotopic heart transplantation..  28:1150-1157. 2009
  • Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation..  28:881-887. 2009
  • Two-stage total cardioaortic replacement for end-stage heart and aortic disease in Marfan syndrome: case report and review of the literature..  28:958-963. 2009
  • The change in B-type natriuretic peptide levels over time predicts significant rejection in cardiac transplant recipients..  28:704-709. 2009
  • Neurocognitive assessments in advanced heart failure patients receiving continuous-flow left ventricular assist devices..  28:542-549. 2009
  • Magnetic resonance imaging-based multiparametric systolic strain analysis and regional contractile heterogeneity in patients with dilated cardiomyopathy..  28:388-394. 2009
  • Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant..  28:395-398. 2009
  • Fusion of aortic valve commissures in patients supported by a continuous axial flow left ventricular assist device..  27:1269-1274. 2008
  • Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support..  27:1286-1292. 2008
  • Infectious complications in extended criteria heart transplantation..  27:1217-1221. 2008
  • Rabbit anti-thymocyte globulin induction therapy does not prolong survival after lung transplantation..  27:547-553. 2008
  • Outcomes in bicaval versus biatrial techniques in heart transplantation: an analysis of the UNOS database..  27:178-183. 2008
  • A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome..  26:1286-1292. 2007
  • Assessing oropharyngeal dysphagia after lung transplantation: altered swallowing mechanisms and increased morbidity..  26:1144-1148. 2007
  • Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria..  26:834-838. 2007
  • Elevated uric acid levels predict allograft vasculopathy in cardiac transplant recipients..  26:498-503. 2007
  • Cytokine gene polymorphisms are not associated with bronchiolitis obliterans syndrome or survival after lung transplant..  25:1330-1335. 2006
  • High frequency of bronchogenic carcinoma after single-lung transplantation..  25:1297-1301. 2006
  • Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006..  25:1024-1042. 2006
  • Topical anesthesia with EMLA reduces pain during endomyocardial biopsy: a randomized trial..  25:1164-1166. 2006
  • Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient..  25:985-988. 2006
  • International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation..  25:745-755. 2006
  • Right ventricle-dominant cardiac sarcoidosis with sparing of the left ventricle..  25:479-482. 2006
  • Cytomegalovirus infection presenting as bronchial polyps in lung transplant recipients..  24:2109-2113. 2005
  • Disruption of iron homeostasis in the lungs of transplant patients..  24:1821-1827. 2005
  • Outcomes with an alternate list strategy for heart transplantation..  24:1781-1786. 2005
  • Recurrence of cardiac sarcoidosis in a heart transplant recipient..  24:1988-1990. 2005
  • Role of Toll-like receptor-driven innate immunity in thoracic organ transplantation..  24:1721-1729. 2005
  • Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation..  24:1327-1331. 2005
  • Upper lobe fibrosis: a novel manifestation of chronic allograft dysfunction in lung transplantation..  24:1260-1268. 2005
  • Coronary artery revascularization in eligible lung transplant recipients..  20:223. 2001
  • Safety and efficacy of pravastatin in pediatric heart transplant recipients..  20:230. 2001
  • Racial and socioeconomic disparities in pediatric heart transplant outcomes in the era of anti-thymocyte globulin induction. 2022
  • Survival difference between high-risk and low-risk CFTR genotypes after lung transplant. 2022
  • Lung transplantation using allografts with more than 8 hours of ischemic time: A single-institution experience. 2021
  • Incidence and outcome of post-transplant lymphoproliferative disorders in lung transplant patients: Analysis of ISHLT Registry. 2020
  • A Multi-Center Study of BAL CXCR3 Chemokines during Allograft Injury after Lung Transplantation 2020
  • Agreement between Fried Frailty Phenotype and Cumulative Deficits Frailty Indices: A Prospective Multi-Center Study 2020
  • Approaches to the Management of Sensitized Lung Transplant Candidates: Findings from an International Survey 2020
  • C-reactive Protein Levels Predict Right Ventricular Failure and Mortality in Patients Undergoing Continuous-Flow Left Ventricular Assist Device Assist Device Implantation: An INTERMACS Analysis 2020
  • De-Novo Human Leukocyte Antigen Allosensitization on HeartMate 3 versus HeartMate II Left Ventricular Assist Device Recipients 2020
  • Detecting Acute Cellular Rejection in Lung Transplant Biopsies by Artificial Intelligence: A Novel Deep Learning Approach 2020
  • EUROMACS-RHF Risk Score and 3D Echocardiography as Predictors of Right Heart Failure after Left Ventricular Assist Device Implantation 2020
  • Effect of Cold Ischemic Time on the Incidence of High-Grade Primary Graft Dysfunction (PGD): A Multicenter Analysis 2020
  • Effect of Time of Intraoperative Circulatory Support on Incidence of High-Grade Primary Graft Dysfunction (PGD): Multicenter Analysis on Use of Extracorporeal Life Support (ECLS) during Lung Transplantation 2020
  • Effects of a Goal Directed Transfusion Protocol on Severe Primary Graft Dysfunction after Lung Transplantation 2020
  • Elevated Serum C-reactive Protein (CRP) Level Predicts Increased Post-Implant Mortality in Patients Undergoing HeartMate 3 LVAD Implantation 2020
  • Extended Post EVLP Cold Preservation Increases Risk of Primary Graft Dysfunction and Mortality 2020
  • Five Year Follow-Up of Staged Bilateral Lung Transplantation for High-Risk Patients with Interstitial Lung Disease: A Matched Case-Control Study 2020
  • HeartMate II Risk Score (HMRS) and MELD-Xi Scores Do Not Predict Mortality in HeartMate 3 LVAD Patients 2020
  • Impact of Heart Failure Drug Therapy on GI Bleeding Rates in LVAD Recipients: An INTERMACS Analysis 2020
  • Impact of Pulse Pressure on Hemocompatibility Related Adverse Events during Support with Continuous Flow Left Ventricular Assist Devices: An Analysis of the INTERMACS Registry 2020
  • Impact of Tricuspid Valve Repair for Moderate Tricuspid Regurgitation at the Time of Left Ventricular Assist Device Implantation on the Occurrence of Right Heart Failure 2020
  • Implications of ECMO Bridging and Salvage Strategies on Mortality and PGD 2020
  • Incidence and Impact of Primary Graft Dysfunction in Adult Heart Transplant Recipients: A Systematic Review and Meta-Analysis 2020
  • Incidence of Driveline Infections and Sepsis in a Contemporary HVAD Population 2020
  • Increased Right Ventricular Assist Device (RVAD) Utilization in Patients with HeartMate 3 Left Ventricular Assist Device (LVAD) in the Post-Approval Era 2020
  • Induction Therapy after Heart Transplantation 2020
  • Infection-Related Morbidity with Continuous-Flow Left Ventricular Assist Systems: A Comprehensive Analysis of the Randomized MOMENTUM 3 Trial 2020
  • Long-Term Neurocognitive Outcomes in LVAD Recipients 2020
  • More Frequent Hospitalizations and Worse Quality of Life with Late Right Heart Failure Compared to Early Right Heart Failure after Left Ventricular Assist as Destination Therapy 2020
  • More Money and More Miles: The Hidden Costs of Donor Procurement with the New Heart Allocation System 2020
  • NanoString Gene Expression Profiling in Chronic Lung Allograft Dysfunction (CLAD) 2020
  • Perioperative Characteristics Associated with Transfusion-Free Lung Transplantation 2020
  • Pre-Formed Donor-Specific Antibodies Impact Long Term Survival of Heart Transplants 2020
  • Predictors and Outcomes of Hemodynamic and Functional LVAD Non-Responders: An Analysis of the INTERMACS Registry 2020
  • Prospective Assessment of Chronic Lung Allograft Dysfunction (CLAD); the Clinical Trials in Organ Transplantation (CTOT) Study Experience 2020
  • Pulmonary Artery Pulsatility Index (PAPi) is a Predictor of Right Ventricular Assist Device (RVAD) Use Following HeartMate 3 LVAD Implantation 2020
  • Pulmonary Microbiome Changes in Lung Transplant Recipients with Gastroesophageal Reflux 2020
  • Sex Differences in Characteristics and Outcomes Following HeartMate 3 Left Ventricular Assist Device Implantation 2020
  • Successful Gene Delivery to Cardiac Allograft with Adeno-Associated Viral Vector Using Ex Vivo Storage Perfusion Platform 2020
  • The NOVEL Study. A Multi-Center Clinical Trial Studying the Safety of Ex Vivo Lung Perfusion 2020
  • The Use of Artificial Intelligence (AI) Machine Learning to Determine Myocyte Damage in Cardiac Transplant Acute Cellular Rejection 2020
  • Use of Low Dose Dopamine in Heart Failure with Preserved Ejection Fraction Patients with Right Ventricular Dysfunction 2020
  • Utilization of Mechanical Circulatory Support Devices and Impact on Outcomes in the New Heart Allocation System: An Analysis of the UNOS Registry 2020
  • Viremic Hepatitis B Donors: A Case of Why It's Time to Further Expand the Donor Pool for Thoracic Transplant 2020
  • The influence of institutional volume on the incidence of complications and their effect on mortality after heart transplantation. 2015
  • Outcomes after percutaneous coronary artery revascularization procedures for cardiac allograft vasculopathy in pediatric heart transplant recipients: A multi-institutional study. 2015
  • Single-lung transplantation in the United States: what happens to the other lung? 2015
  • Efficacy and durability of central oversewing for treatment of aortic insufficiency in patients with continuous-flow left ventricular assist devices. 2014